E. Leo

发表

Potent and selective antisense oligonucleotides targeting the transforming growth factor beta (TGF-β) isoforms in advanced glaucoma: a preclinical evaluation

M. Janicot, L. Moons, I. Stalmans, 2016 .

Molecular basis for CD 40 signaling mediated by TRAF 3

Hao Wu, C. Ni, K. R. Ely, 2000 .

TGF-Δ isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity

M. Janicot, M. Riemenschneider, M. Proescholdt, 2015, Oncotarget.

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

H. Einsele, L. Kanz, A. Mackensen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapeutic induction of long-term remission in metastatic medulloblastoma

A. Lindemann, E. Leo, P. Schlegel, 1997, Journal of Neuro-Oncology.

Differential Requirements for Tumor Necrosis Factor Receptor-associated Factor Family Proteins in CD40-mediated Induction of NF-κB and Jun N-terminal Kinase Activation*

K. R. Ely, John Calvin Reed, J. Zapata, 1999, The Journal of Biological Chemistry.

95 MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy

Jennifer D. Oduro, R. Simon, C. Fraune, 2021, Journal for ImmunoTherapy of Cancer.

Preclinical anti‐myeloma activity of the novel HDAC‐inhibitor JNJ‐26481585

H. Einsele, R. Bargou, M. Chatterjee, 2010, British journal of haematology.

CD40‐mediated activation of Ig‐Cγ1‐ and Ig‐Cϵ germ‐line promoters involves multiple TRAF family proteins

John Calvin Reed, J. Zapata, E. Leo, 1999 .

Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma

R. Parwaresch, A. Ho, A. Benner, 2004, European journal of haematology.

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

E. Estey, H. Dombret, G. Martinelli, 2012 .

Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy

A. Krämer, A. Ho, R. Hehlmann, 2002, Annals of Hematology.

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma

T. Hielscher, A. Krämer, A. Ho, 2012, American journal of hematology.

Commercial LightCycler®-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma

A. Ho, M. Hensel, M. Kornacker, 2008, Annals of Hematology.

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

E. Estey, H. Döhner, H. Dombret, 2012 .

The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.

A. Ho, A. Benner, M. Hensel, 2006, Leukemia research.

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

E. Estey, H. Döhner, H. Dombret, 2011 .

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

P. Kufer, P. Baeuerle, C. Brandl, 2006, Cancer Immunology, Immunotherapy.

Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases

A. Ho, M. Kornacker, A. Kraemer, 2002, Annals of Hematology.

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

H. Einsele, P. Kufer, A. Wolf, 2008, Science.

Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

J C Reed, John Calvin Reed, K. Welsh, 1999, The EMBO journal.

TRAF1 Is a Substrate of Caspases Activated during Tumor Necrosis Factor Receptor-α-induced Apoptosis*

John Calvin Reed, K. Welsh, Q. Deveraux, 2001, The Journal of Biological Chemistry.

The Drosophila Tumor Necrosis Factor Receptor-associated Factor-1 (DTRAF1) Interacts with Pelle and Regulates NFκB Activity*

A. Godzik, S. Wasserman, John Calvin Reed, 2000, The Journal of Biological Chemistry.

One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?

A. Ho, A. Benner, M. Hensel, 2006, Leukemia research.

Molecular basis for CD40 signaling mediated by TRAF3.

J C Reed, C. Ni, K. R. Ely, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma.

P. Schirmacher, M. Peters, P. Baeuerle, 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017, PloS one.

Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2) in glaucoma filtration surgery

H. Thieme, N. Pfeiffer, K. Lorenz, 2017 .

TRAF Family Proteins Interact with the Common Neurotrophin Receptor and Modulate Apoptosis Induction*

C. Hauser, John Calvin Reed, J. Zapata, 1999, The Journal of Biological Chemistry.

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.

T. Raum, P. Baeuerle, D. Weckermann, 2006, European journal of cancer.

First-inhuman phase I study of ISTH 0036 , an antisense oligonucleotide selectively targeting transforming growth factor beta 2 ( TGF-β 2 ) , in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017 .

JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies

C. Blattner, M. Janicot, P. Verhasselt, 2008 .

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

S. H. van der Burg, S. von Felten, R. Dummer, 2023, Nature communications.

CD40-mediated activation of Ig-Cgamma1- and Ig-cepsilon germ-line promoters involves multiple TRAF family proteins.

John Calvin Reed, J. Zapata, E. Leo, 1999, European journal of immunology.

A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo

M. Page, R. Bargou, K. Bommert, 2008 .

The Drosophila Tumor Necrosis Factor Receptor-associated Factor-1 (DTRAF1) Interacts with Pelle and Regulates NFκB Activity*

A. Godzik, S. Wasserman, John Calvin Reed, 2000, Journal of Biological Chemistry.